CD274 and neoplasm: The expression of PD-L1 is often used as a biomarker to predict response to ICIs; however, its presence does not guarantee therapeutic efficacy, as the tumor microenvironment's overall immunogenicity plays a crucial role in determining outcomes [162–164].